Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

CORAL: Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (clinicaltrials.gov) - P3 | N=2226 | Terminated | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Terminated; Sponsor decision

Trial termination • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

4304 - The Pneumovax 23 Vaccine is Going Away: What Now: Update on Tools for Diagnosing Immunodeficiencies (AAAAI 2026) - "The landscape of pneumococcal vaccines is shifting, with the phase-out of Pneumovax 23 and increasing use of Prevnar 20/21. This session will also prepare you to recognize these diseases and prepare your practice for the risks and complications associated with these infections. Learning Objectives: - Explain guidelines on diagnostic vaccination in the evaluation of immunodeficiency- Describe how immunomodulatory medications affect vaccine response- Discuss vaccine preventable diseases in the era of declining herd immunityCME: 1.25CE: 1.25Participation: 1.25"

Immunology • Infectious Disease • Pneumococcal Infections • Primary Immunodeficiency

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Hematological Disorders • Infectious Disease • Pneumococcal Infections • Sickle Cell Disease

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials. (PubMed, Vaccine) - P2 | "Multiple formulations of IVT PCV-25, a vaccine designed to cover pneumococcal serotypes prevalent in LMICs, were well tolerated and immunogenic in healthy adults. As adult immunogenicity is not fully predictive for infants, further development will evaluate safety and immunogenicity in the target infant population."

Clinical • Journal • Infectious Disease • Pneumococcal Infections

Cost-effectiveness analysis of a 20-valent pneumococcal conjugate vaccine for pneumococcal disease prevention in the Slovak pediatric population. (PubMed, J Med Econ) - "Direct and indirect vaccine effects (VE) were estimated from vaccine impact, effectiveness, and clinical studies of PCV7 and PCV13...Implementing PCV20 into the Slovakian pediatric NIP is projected to yield the most significant clinical and economic benefits compared to the two lower-valent PCVs, due to its more extensive protection against a broader range of pneumococcal serotypes. Despite an additional cost of dose and visit, PCV20 was estimated to be cost-effective at the Slovak WTP threshold versus other SoC options over a 10-year time horizon."

HEOR • Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion

Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective. (PubMed, Cost Eff Resour Alloc) - No abstract available

HEOR • Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (clinicaltrials.gov) - P3 | N=896 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial. (PubMed, Hum Vaccin Immunother) - P3 | "Consistent with previous trials, PCV20 elicited robust immune responses to all 20 serotypes following a single dose and was well tolerated with an acceptable safety profile in Indian adults ≥18 y of age. NCT05875727."

Journal • P3 data • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Seema Bhat | Trial completion date: Dec 2025 ➔ Oct 2026 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Small Lymphocytic Lymphoma

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (clinicaltrials.gov) - P3 | N=4000 | Recruiting | Sponsor: Vaxcyte, Inc.

New P3 trial • Infectious Disease • Pneumococcal Infections

A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan (clinicaltrials.gov) - P3 | N=541 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed | N=401 ➔ 541

Enrollment change • Trial completion • Infectious Disease • Pneumococcal Infections

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia (clinicaltrials.gov) - P=N/A | N=846279 | Not yet recruiting | Sponsor: Pfizer

New trial • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Genetic Disorders • Hematological Disorders • Infectious Disease • Pneumococcal Infections • Sickle Cell Disease

A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Pfizer | N=100 ➔ 200

Enrollment change • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Sep 2025 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Jun 2026

Real-world evidence • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (clinicaltrials.gov) - P1 | N=400 | Active, not recruiting | Sponsor: Pfizer | N=158 ➔ 400

Enrollment change • Infectious Disease • Pneumococcal Infections

Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia. (PubMed, Vaccine) - "This cost-effectiveness analysis estimated that adoption of PCV20 into the Australian paediatric NIP would be dominant versus PCV13 and PCV15, leading to health benefits and cost-savings."

Journal • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan (ISPOR-EU 2025) - "CEA suggests use of PCV20—in lieu of current Taiwan CDC recommendations for pneumococcal vaccination in high-risk adults aged 18-64 years and all adults aged ≥65 years—would be cost saving and represent an efficient use of healthcare resources and would substantially reduce the numbers of cases and deaths due to pneumococcal disease."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants (ISPOR-EU 2025) - "Vaccine effectiveness (VE) was extrapolated from PCV13 effectiveness and PCV7 efficacy studies... PCV20 vaccination is projected to provide greater protection against pneumococcal disease in French infants than PCV15, regardless of VE assumptions or dosing schedules. These results support the preferential use of PCV20 to maximize disease prevention in the first year of life."

Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns (ASH 2024) - "All 8 centers offered ide-cel while cilta-cel was offered by 6...Other vaccines were given less frequently with Prevnar 20 at 64.3%, Pentavalent (DPT, Hep B, H. influenzae) at 57%, Hep B virus (HBV), RZV, and MCV4 each at 50%. Pneumovax 23 and MMR (live) were recommended by 42.8%, HPV by 35.7%, and VZV (live) by 21.4%...While there are limitations in the generalizability of these practices, these findings demonstrate marked differences in clinical practices across USMIRC centers. Further studies are needed to correlate these practices with downstream infection rates and to allow the development of consensus guidelines for both higher and lower-volume centers."

CAR T-Cell Therapy • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Hepatitis B • Infectious Disease • Influenza • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • CD4

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine From Lower-Valent Vaccines in the French Pediatric Population (ISPOR-EU 2025) - "This study predicted that infant immunization with PCV20 was the most cost-effective option compared with PCV13 and PCV15. These results could help decision-makers implement the optimal PCV strategy in the French pediatric NIP."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Invasive Pneumococcal Disease at Eight Children's Hospitals in the United States, 2018-2023. (PubMed, Pediatr Infect Dis J) - "PCV13 serotypes (especially 3, 19A and 19F) continue to account for 30% of IPD in US children 8-13 years after PCV13 was introduced. Vancomycin should still be included in empiric treatment of bacterial meningitis in children. The introduction of PCV20 for routine administration to infants could result in further reductions in IPD in children."

Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections

Cost-Effectiveness Assessment of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among At-Risk and High-Risk Adults in India (ISPOR-EU 2025) - "Compared to PCV13 ◊PPV23, PCV20 in at-/high-risk older adults would be cost-saving and cost-effective from both private and government payer perspectives. Furthermore, from private payer perspective, PCV20 would be cost-effective compared with all other vaccination strategies considered."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases